Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance
Jennifer S Carew1, Steffan T Nawrocki1, Francis J Giles1, John L Cleveland21The CTRC Institute for Drug Development, University of Texas Health Science Center San Antonio, San Antonio, TX, USA; 2The Department of Cancer Biology, The Scripps Research Institute, Jupiter, FL, USAAbstract: Autophagy is...
Guardado en:
Autores principales: | Jennifer S Carew, Steffan T Nawrocki, Francis J Giles, John L Cleveland |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c53d4c8306034bdb8fb9674d50370ccc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity
por: Marslin G, et al.
Publicado: (2015) -
Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Alexander G. Raufi, et al.
Publicado: (2021) -
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
por: Clara I Aceves-Luquero, et al.
Publicado: (2009) -
Mesenchymal stem cells in cancer progression and anticancer therapeutic resistance
por: Xiuyun Xuan, et al.
Publicado: (2021) -
Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.
por: Jérome Kluza, et al.
Publicado: (2011)